A federal case exposing the “Ketamine Queen” and doctors in the supply chain behind Matthew Perry’s fatal overdose is set to shake up America’s at-home drug industry.
Story Highlights
- A so-called “Ketamine Queen” faces a September 2025 trial for allegedly selling Matthew Perry the fatal dose of ketamine.
- The case has exposed regulatory gaps in the booming at-home ketamine therapy industry, raising alarms about public safety and medical ethics.
- Licensed doctors and Perry’s assistant have pleaded guilty in a broader federal crackdown on illegal drug supply chains.
- Experts and officials warn that the case could prompt sweeping new restrictions and oversight on at-home controlled substance distribution in the U.S.
Federal Investigation Targets Drug Supply Chains Behind Celebrity Overdose
Federal prosecutors have charged a woman dubbed the “Ketamine Queen” with selling actor Matthew Perry the dose of ketamine that led to his death. She is set to stand trial in September 2025, marking a pivotal moment in a sweeping federal probe that has also ensnared two licensed physicians and Perry’s assistant. The investigation, launched after Perry was found dead at his Los Angeles home in October 2023, uncovered a complex network of medical professionals and alleged street-level dealers providing controlled substances to the late star.
‘Ketamine Queen’ accused of selling Matthew Perry fatal dose gets September trial date https://t.co/pBOUcHoIzA
— KNOP News 2 (@KNOPNews2) August 7, 2025
Federal authorities have made clear their intent to hold accountable not only street-level dealers but also licensed physicians who cross legal and ethical boundaries. As the case moves forward, the trial of the accused woman will serve as a bellwether for how aggressively the government will pursue those implicated in celebrity drug deaths, regardless of their professional status.
Medical Professionals and At-Home Ketamine Therapy Under Fire
The broader federal investigation revealed that at-home ketamine therapy—often prescribed or supplied through telemedicine and non-traditional clinics—has outpaced regulatory oversight, creating opportunities for abuse. Dr. Salvador Plasencia, a licensed physician known as “Dr. P.,” pleaded guilty in July 2025 to supplying ketamine to Perry, agreeing to surrender his medical license and face prison time. Perry’s assistant, Kenneth Iwamasa, also pleaded guilty to related charges. Medical professionals’ involvement raises serious questions about the responsibilities and limits of prescribers, especially as new drug delivery models blur the lines between therapy and illegal distribution.
Celebrity Status, Legal Accountability, and Public Safety Risks
The death of a beloved television star has brought renewed attention to the risks of unsupervised substance use, the responsibilities of providers, and the broader cultural problem of celebrity addiction. The involvement of both medical professionals and unlicensed suppliers demonstrates the extent to which high-profile individuals can access controlled substances through multiple channels, often with tragic results. The upcoming trial is likely to intensify calls for lawmakers to address these regulatory gaps, lest further tragedies occur.
Short-term, the fallout includes increased scrutiny of at-home ketamine providers and the likelihood of new restrictions on controlled substance distribution. Long-term, the case may set legal and regulatory precedents affecting how—and whether—these therapies are offered in the future. The entertainment industry, medical community, and affected families are all bracing for the implications, while the public waits to see if justice will be served and if real reform will follow. As with prior celebrity overdose cases, the legacy of Matthew Perry’s death could be measured not just in legal outcomes, but in the reforms it prompts throughout American medicine and law.
Sources:
‘Ketamine Queen’ accused of selling Matthew Perry fatal dose gets September trial, ABC News
